StockPreacher.com Issues Trading Overview for Oncolytics Biotech Inc.

• Press Release
• Source: StockPreacher
• On 6:50 am EDT, Wednesday October 7, 2009

DALLAS, Oct. 7, 2009 (GLOBE NEWSWIRE) -- StockPreacher.com announces an investment report featuring Oncolytics Biotech Inc. (Nasdaq:ONCY - News). The report includes financial and investment analysis, analyst consensus, and pertinent industry information you need to know to make an educated investment decision.

Related Quotes

Symbol	Price	Change
AGEN	0.90	-0.06

{"s" : "agen,arql,infi,oncy,supg","k" : "c10,l10,p20,t10","o" : "","j" : ""}

The investment report on Oncolytics Biotech Inc. (Nasdaq:ONCY - News) should be of particular interest to other biotechnology companies: Antigenics Inc. (Nasdaq:AGEN - News), Infinity Pharmaceuticals Inc. (Nasdaq:INFI - News), ArQule Inc. (Nasdaq:ARQL - News) and Supergen Inc. (Nasdaq:SUPG - News).

The full report is available at: http://www.stockpreacher.com/n/ONCY

Oncolytics Biotech Inc. (ONCY) is a development stage biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. The Company's clinical program includes a variety of phase I/II and phase II human trials using REOLYSIN, its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. REOLYSIN is the Company's potential cancer therapeutic. ONCY's products under development have not been manufactured on a commercial scale.

In the report, the analyst notes:

"The Company has been granted approximately 200 patents worldwide, including 30+ U.S. patents and 11 Canadian patents covering REOLYSIN technology and modified herpes and adenoviruses. In September, ONCY was granted with its 32nd U.S. Patent, No. 7,582,289, entitled Viruses for the Treatment of Cellular Proliferative Disorders. The patent claims cover methods of using modified parapoxvirus orf virus to treat Ras-mediated cancers. The Company has now secured five U.S. patents covering the use of other oncolytic viruses to treat Ras-mediated cancers.

"In September, the Cancer Therapy Research Center at the University of Texas Health Science Center started patient enrolment in a U.S. phase II clinical trial using intravenous administration of REOLYSIN in combination with paclitaxel and carboplatin in patients with metastatic melanoma. The trial is a single arm, open-label, phase II study of REOLYSIN given intravenously with paclitaxel and carboplatin every three weeks. It is anticipated that up to 43 patients will be treated in the study."

To read the entire report visit: http://www.stockpreacher.com/n/ONCY

See what investors are saying about these stocks at: http://www.stockhideout.com/

StockPreacher.com is a small-cap research and investment commentary provider. StockPreacher.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on StockPreacher, please visit: http://www.stockpreacher.com

StockPreacher.com Disclosure

StockPreacher.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. StockPreacher.com is a Web site wholly-owned by BlueWave Advisors, LLC. Please read our report and visit our Web site, StockPreacher.com, for complete risks and disclosures.

StockPreacher.com
Jeff Bishop
(469)-252-3505
press@beaconequity.com